Trial Profile

A PHASE 1B, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND PRELIMINARY EFFICACY OF CEMSIDOMIDE IN COMBINATION WITH ELRANATAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA SUBJECTS

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemsidomide (Primary) ; Dexamethasone (Primary) ; Elranatamab (Primary)
Indications Multiple myeloma
Focus Adverse reactions
Sponsors C4 Therapeutics

12 Dec 2025 Status changed from planning to not yet recruiting.
17 Oct 2025 According to C4 Therapeutics media release, trial expected to initiate in Q2 2026.
01 Oct 2025 According to C4 Therapeutics media release, the company announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO), a B-cell maturation antigen CD3 targeted bispecific antibody (BCMAxCD3 bispecific), to C4T for its upcoming Phase 1b trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com